Chemours Co (CC)

Insider Trading Filed: 2026-05-08

Key Insights

Director Mary B. Cranston acquired 7,182 shares of common stock on 05/06/2026 at $0 price, indicating this was likely a compensation award rather than a market purchase.
The filing notes an administrative correction to prior Form 4s, with total holdings adjusted to 106,830.0129 shares including deferred stock units and dividend equivalent units, suggesting prior reporting discrepancies that have now been reconciled.
As a director-level insider, Cranston's acquisition through equity compensation (deferred stock units) reflects standard board compensation practices rather than voluntary market purchases, providing limited signal about management confidence in the stock.

Insider Trading Filed: 2026-05-08

Key Insights

Director Leslie M Turner acquired 7,182 shares of Chemours common stock on 05/06/2026 with $0 consideration, indicating these were compensation-related stock units rather than open-market purchases.
Turner's total beneficial ownership increased to 24,603.3891 shares following the transaction, with the acquisition comprising deferred stock units and dividend equivalent units that convert upon board separation.
This transaction represents routine director compensation and does not signal material insider confidence or concern about the company's valuation, as the acquisition was non-discretionary equity compensation.

Insider Trading Filed: 2026-05-08

Key Insights

Director Pamela Fletcher acquired 7,182 shares of Chemours common stock on 05/06/2026 at no cost, representing stock units that convert upon separation from service, indicating this is a vesting/compensation event rather than open market buying.
Fletcher's total beneficial ownership increased to approximately 32,383 shares following the transaction, suggesting established accumulated equity compensation from her board service.
The transaction involves deferred stock units and dividend equivalent units, which are typical director compensation mechanisms that do not signal insider confidence or concern about company valuation.

Insider Trading Filed: 2026-05-08

Key Insights

Director Alister Cowan acquired 7,182 shares of common stock on 05/06/2026 at no cost, representing a vesting of restricted stock units rather than open market purchases.
Cowan's total beneficial ownership increased to approximately 43,881 shares following this transaction, indicating meaningful accumulated equity stake as a board member.
The acquisition was made pursuant to equity compensation rather than discretionary buying, suggesting this reflects normal director compensation practices rather than insider conviction about stock valuation.
The filing shows no derivative securities or options activity, indicating the transaction involved only restricted stock unit conversion upon service continuation.

Insider Trading Filed: 2026-05-08

Key Insights

Director Courtney Mather acquired 7,182 shares of common stock on 05/06/2026 at no cost, indicating a stock unit vesting event rather than open market purchase, suggesting compensation tied to board service.
Total beneficial ownership increased to 21,642.7173 shares following the transaction, with the acquisition comprised of deferred stock units and dividend equivalent units that convert upon separation from the board.
The filing represents a routine insider transaction typical of director compensation practices; the zero purchase price and vesting mechanism indicate this is part of standard equity compensation rather than a discretionary market transaction.
As a director-only position with no officer title, this transaction provides limited insight into management's confidence in company prospects, making it less significant than officer or substantial shareholder transactions.

Insider Trading Filed: 2026-05-08

Key Insights

Director Erin Kane acquired 7,182 shares of Chemours common stock on 05/06/2026 with zero purchase price, indicating this was a compensation-related transaction (likely restricted stock units vesting) rather than open market buying.
Kane's total beneficial ownership increased to approximately 74,063 shares following the transaction, with holdings comprised of deferred stock units and dividend equivalent units, showing long-term alignment with shareholder interests.
The transaction was executed through stock units that convert one-for-one upon separation from service on the Board, which is a standard equity compensation mechanism for directors but does not signal insider confidence in near-term stock appreciation.

Insider Trading Filed: 2026-05-08

Key Insights

Director Livingston acquired 7,182 shares of common stock on 05/06/2026 at $0 price, indicating these were received as compensation rather than a market purchase, reflecting standard director equity grants.
Total beneficial ownership following the transaction is 30,807.855 shares, comprised of direct holdings and deferred/dividend equivalent stock units that convert upon board separation, showing meaningful accumulated equity stake.
The filing documents a routine equity compensation event for a board director rather than a significant insider trading signal, as the $0 price and nature of restricted stock units are typical for director remuneration.

Insider Trading Filed: 2026-05-08

Key Insights

Director Sean D. Keohane acquired 7,182 shares of Chemours common stock on 05/06/2026 at no cost, representing a stock unit conversion upon vesting rather than open market purchase.
The acquisition increased Keohane's beneficial ownership to 72,555.1777 shares, indicating established and growing stake in the company as a board member.
The transaction involved deferred stock units and dividend equivalent units converting to common stock, a typical compensation mechanism for directors that aligns interests with shareholders but does not signal strong conviction buying.

Insider Trading Filed: 2026-05-08

Key Insights

Director Kava Joseph Daniel acquired 7,182 shares of Chemours common stock on 05/06/2026 through stock units that convert upon separation from service, bringing total beneficial ownership to 24,603.3891 shares.
The acquisition was made at $0 price, indicating this is a compensation-related grant or vesting of deferred stock units and dividend equivalent units rather than an open market purchase.
As a Director, this insider transaction represents routine equity compensation rather than discretionary buying activity, providing limited insight into management's confidence in the stock's future performance.
The filing is dated 2026-05-08, which is a future date, suggesting this is a hypothetical or test filing that should not be used for actual investment decisions.

Insider Trading Filed: 2026-05-08

Key Insights

Director George R. Brokaw acquired 7,182 shares of Chemours common stock on May 6, 2026 at $0 consideration, indicating this was a non-cash equity award (deferred stock units or dividend equivalent units) rather than a market purchase.
Following this transaction, Brokaw's total beneficial ownership increased to approximately 21,643 shares, demonstrating continued alignment with shareholder interests through equity compensation.
The use of a Rule 10b5-1 plan for this transaction suggests pre-planned, systematic equity accumulation by an insider, which is a compliance-positive indicator for insider trading rules.

Quarterly Report Filed: 2026-05-05

Key Insights

Filing contains extensive XBRL tagging for complex financial instruments, environmental liabilities, and multi-segment operations, indicating Chemours is managing significant debt obligations and PFAS-related legal contingencies that require detailed disclosures.
Multiple restructuring program references (2024 and 2026) and references to various credit facilities (secured and unsecured) suggest the company is undergoing operational optimization while managing substantial leverage that could impact cash flow and shareholder returns.
Environmental and litigation matters are heavily documented including PFOA settlements, benzene-related illness claims, and on-site remediation obligations, representing material long-term liabilities that warrant close monitoring for future charge impacts on profitability.

Current Report Filed: 2026-05-05

Key Insights

Chemours released Q1 2026 financial results on May 5, 2026, with an earnings call scheduled for May 6, 2026, indicating ongoing investor communication about quarterly performance.
The company is providing an investor presentation alongside earnings results, suggesting management is prepared to discuss strategic initiatives and financial outlook with stakeholders.
This is a routine quarterly earnings disclosure filed under Item 2.02, with no indication of material events, guidance changes, or significant business developments that would materially impact the stock.

Current Report Filed: 2026-04-30

Key Insights

All 11 director nominees were elected with strong shareholder support, with voting percentages ranging from 95.8% to 99.3%, indicating solid confidence in board leadership and governance.
The 2026 Equity and Incentive Plan was approved with 108.8 million votes in favor but faced meaningful opposition with 3.7 million votes against, suggesting some shareholder concerns about compensation or equity dilution.
The advisory say-on-pay vote passed overwhelmingly with 110.1 million votes for and only 2.5 million against, demonstrating strong shareholder approval of executive compensation practices.
PricewaterhouseCoopers LLP was ratified as independent auditor with 128.3 million votes in favor and minimal opposition (813,925 against), showing stable audit relationship and shareholder confidence in financial oversight.

Insider Trading Filed: 2026-04-01

Key Insights

Courtney Mather, a director of Chemours Co (CC), acquired 1,305 deferred stock units on March 31, 2026 at a price of $22.03 per unit.
This acquisition increases Mather's total beneficial ownership to 7,552.3528 units, representing a direct ownership stake in the company.
Insider buying can be a positive signal, indicating the director's confidence in the company's future prospects.

Current Report Filed: 2026-03-12

Key Insights

Chemours completed the private offering of $700 million in 7.875% Senior Notes due 2034, which will be used to fund the redemption of existing senior notes and provide additional liquidity.
The Notes have customary terms and conditions, including a make-whole provision for early redemption and a change-of-control put option, which provide flexibility to the company.
The proceeds from the Notes offering will help Chemours optimize its capital structure and reduce interest expense going forward.

Current Report Filed: 2026-02-26

Key Insights

Chemours is raising $700 million in senior unsecured notes due in 2034, an increase from the previously announced $600 million offering.
The notes will carry a 7.875% interest rate, indicating the company is likely seeking capital for expansion or refinancing purposes.
The timing of the debt offering, in the midst of current market conditions, suggests Chemours sees favorable opportunities for growth or improved financing terms.

Annual Report Filed: 2026-02-24

Key Insights

Chemours Co. reported a decline in revenue across its key business segments over the past 5 years, indicating potential challenges in the company's core operations.
The company has accrued significant environmental liabilities, which could pose risks to its financial performance and cash flows going forward.
Chemours has undertaken restructuring efforts, including facility closures and asset-related charges, which could impact its operational efficiency and profitability in the near term.

Current Report Filed: 2026-02-19

Key Insights

Chemours reported strong Q4 2025 and full year 2025 financial results, indicating the company's business performance continues to be robust.
The company plans to hold an investor presentation on February 20, 2026, providing an opportunity for investors to gain further insights into the company's operations and strategic direction.
Chemours' stock ticker symbol (CC) and its listing on the New York Stock Exchange suggest the company's securities are publicly traded and actively monitored by investors.

Current Report Filed: 2026-01-16

Key Insights

Chemours is selling 10 parcels of land in Taiwan for approximately $360 million, which will be used to reduce the company's debt obligations.
The sale is expected to be completed through one or more closings by mid-year 2026, subject to certain closing conditions and local regulatory approval.
The transaction was negotiated on an arms-length basis with four affiliated entities, indicating it was a strategic decision rather than a related-party transaction.

Insider Trading Filed: 2026-01-05

Key Insights

Courtney Mather, a director of Chemours Co (CC), acquired 2,226 deferred stock units on 2025-12-31, indicating continued confidence in the company's long-term prospects.
The deferred stock units will become payable upon Mather's termination of service as a director, aligning her interests with those of long-term shareholders.
The acquisition of the deferred stock units at a price of $11.79 per unit suggests Mather believes the stock is undervalued at current market prices.

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Important Information